Figure 3. miR-30d Is Enriched in Feces from EAE Animals at Peak Disease and in Feces from Untreated MS Patients.
(A-B), RNA was isolated from feces of non-immunized (naïve) mice, mice immunized with OVA or mice immunized with MOG at 15 days post immunization (peak EAE). (A) Fold change of the changed miRNAs in top 20 abundant miRNAs by small RNA-Seq. Data were normalized to total reads. * P<0.05, ** P<0.01, n=5 each group, Error bars denote mean ± SEM, two-way ANOVA two-stage step-up method of Benjamini, Krieger and Yekutieli multiple comparing to MOG-immunized mice. (B) higher expression of miR-30d-5p in MOG-immunized EAE peak was verified by qPCR; Non-immunized n=9, OVA-immunized n=12, MOG-immunized n=12, Error bars denote mean ± SEM, one-way ANOVA Dunnett’s multiple comparisons comparing to MOG-immunized mice. (C-D), RNA was isolated from feces of non-treated relapsing-remitting MS patients and healthy controls (HC). (C) Fold change of the top 25 miRNAs by small RNA-Seq. Data were normalized to total reads. * P<0.05, **** P<0.0001, n=10 each group; Error bars denote mean ± SEM, two-way ANOVA two-stage step-up method of Benjamini, Krieger and Yekutieli. (D) higher expressions of miR-30d-5p, miR-7706 and miR-1246 in MS patients were verified by qPCR, n=12 each group, Error bars denote median ± 95%CI, Mann Whitney test. n.s.= not significant, * P<0.05, ** P<0.01, *** P<0.001.